Nuvalent, Inc.
NUVL
Kedudukan dalam Saham
#2115
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Harga Saham
$123.96
Disegerakkan terakhir: 2026-07-21
Modal Pasaran
$9.75B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
27.56%
Negara
US
Perdagangan Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Nisbah P/E bagi Nuvalent, Inc. (NUVL)
Nisbah P/E pada October 2026 TTM: -20.46
Menurut laporan kewangan dan harga saham terkini Nuvalent, Inc., nisbah P/E semasa (TTM) ialah -20.46. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -33.95.
Sejarah nisbah P/E bagi Nuvalent, Inc. dari 2019 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -20.46 | 2.58% |
| 2024 | -19.94 | -41.27% |
| 2023 | -33.95 | 87.85% |
| 2022 | -18.07 | 101.89% |
| 2021 | -8.95 | -69.61% |
| 2020 | -29.45 | -61.58% |
| 2019 | -76.66 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -240.71% |
US
|
|
| -28.36 | 38.64% |
US
|
|
| -24.57 | 20.10% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -248.27% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.